CYP19 Inhibitors
Items 1 to 10 of 18 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $32.00 $210.00 $720.00 $1128.00 $2302.00 $3066.00 $5106.00 | 22 | |
Apigenin functions as a modulator of CYP19, exhibiting unique interactions that influence aromatase activity. Its structure allows for non-competitive binding, altering the enzyme's conformation and affecting estrogen biosynthesis. This modulation can impact various metabolic pathways, as apigenin interacts with key residues within the enzyme's active site. Additionally, its hydrophobic characteristics may enhance its affinity for lipid environments, potentially influencing enzyme dynamics and substrate availability. | ||||||
Butein | 487-52-5 | sc-202510 sc-202510A | 5 mg 50 mg | $172.00 $306.00 | 8 | |
Butein acts as a selective inhibitor of CYP19, engaging in specific molecular interactions that disrupt aromatase function. Its unique structural features facilitate competitive binding at the enzyme's active site, leading to altered kinetics in estrogen production. The presence of hydroxyl groups enhances its solubility in biological systems, promoting effective interaction with the enzyme. Furthermore, butein's ability to form hydrogen bonds may stabilize transient enzyme-substrate complexes, influencing metabolic regulation. | ||||||
Exemestane-19-d3 | sc-218454 | 1 mg | $583.00 | |||
Exemestane-19-d3 is a potent inhibitor of CYP19, characterized by its unique isotopic labeling that enhances its metabolic tracking. This compound exhibits distinct binding affinity due to its structural modifications, which allow for selective interaction with the aromatase enzyme. Its kinetic profile reveals a competitive inhibition mechanism, altering the enzyme's catalytic efficiency. Additionally, the presence of deuterium atoms may influence the stability of enzyme-ligand complexes, providing insights into metabolic pathways. | ||||||
Liarozole hydrochloride | 145858-50-0 | sc-204055 sc-204055A | 10 mg 50 mg | $159.00 $500.00 | 1 | |
Liarozole hydrochloride functions as a selective inhibitor of CYP19, showcasing unique interactions with the aromatase enzyme. Its structural features facilitate a specific binding mode, leading to altered enzyme conformation and reduced catalytic activity. The compound's reaction kinetics indicate a non-competitive inhibition pattern, which may affect substrate accessibility. Furthermore, its solubility characteristics enhance its interaction dynamics within biological systems, influencing metabolic pathways. | ||||||
Aromatase Inhibitor I | 331684-05-0 | sc-221269 | 1 mg | $238.00 | ||
Aromatase Inhibitor I exhibits a distinctive mechanism of action as a CYP19 inhibitor, characterized by its ability to form stable complexes with the aromatase enzyme. This compound engages in specific hydrogen bonding and hydrophobic interactions, which modulate the enzyme's active site. Its kinetic profile reveals a unique competitive inhibition, impacting substrate turnover rates. Additionally, its lipophilic nature influences membrane permeability, potentially altering cellular uptake and distribution. | ||||||
Letrozole-d4 | 1133712-96-5 | sc-280910 | 1 mg | $330.00 | ||
Letrozole-d4 functions as a selective inhibitor of CYP19, showcasing unique molecular interactions that disrupt estrogen biosynthesis. Its deuterated structure enhances metabolic stability, allowing for prolonged enzyme engagement. The compound exhibits distinct binding affinity, leading to altered reaction kinetics that favor reduced aromatase activity. Furthermore, its physicochemical properties, including solubility and partitioning behavior, may influence its distribution in biological systems, affecting overall efficacy. | ||||||
Aminoglutethimide | 125-84-8 | sc-207280 sc-207280A sc-207280B sc-207280C | 1 g 5 g 25 g 100 g | $41.00 $143.00 $530.00 $2020.00 | 2 | |
Aminoglutethimide inhibits aromatase by blocking the conversion of cholesterol to pregnenolone, an early step in steroid biosynthesis, leading to decreased estrogen production. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $85.00 $144.00 | 5 | |
Letrozole is a nonsteroidal aromatase inhibitor that suppresses estrogen biosynthesis by competitively binding to the aromatase enzyme, leading to reduced estrogen levels. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $90.00 | 1 | |
Anastrozole is a nonsteroidal aromatase inhibitor that binds reversibly to the heme group of the cytochrome P450 enzyme CYP19, blocking the conversion of androgens to estrogens. | ||||||
Apigenin-d5 | 263711-74-6 | sc-207297 | 1 mg | $342.00 | ||
Apigenin-d5 acts as a modulator of CYP19, characterized by its unique isotopic labeling that alters its metabolic profile. This compound engages in specific interactions with the enzyme's active site, potentially influencing substrate recognition and binding dynamics. Its distinct isotopic composition may also affect the rate of metabolic turnover, leading to variations in aromatase inhibition. Additionally, its solubility characteristics can impact its bioavailability and interaction with cellular membranes. | ||||||